The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges
Journal of Controlled Release · 2025-03 · 379 · 421-439
DOI: 10.1016/j.jconrel.2025.01.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Rosy Ghanem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200, Brest, France; CHU de Brest, Service de Génétique Médicale et de Biologie de la Reproduction, F-2920…. Hauptthemen laut MEDLINE: Lung Diseases, Drug Delivery Systems. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 318 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conseil Régional de Bretagne, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Aerosol delivery represents a rapid and non-invasive way to directly reach the lungs while escaping the hepatic first-pass effect. The development of pulmonary drugs for respiratory diseases such as cystic fibrosis, lung infections, pulmonary fibrosis or lung cancer requires an enhanced understanding of the relationships between the natural physiology of the respiratory system and the pathophysiology of these conditions. This knowledge is crucial to better predict and thereby control drug deposition. Moreover, aerosol administration faces several challenges, including the pulmonary tract, immune system, mucociliary clearance, the presence of fluid on the airway surfaces, and, in some cases, bacterial colonisation. Each of them directly influences on the bioavailability of the active molecule. In addition to these challenges, particle size and the device used to administer the treatment are critical factors that can significantly impact the biodistribution of the drugs. Nanoparticles are very promising in the development of new formulations for aerosol drug delivery, as they can be fine-tuned to reach the entire pulmonary tract and overcome the difficulties encountered along the way. However, to properly assess drug delivery, preclinical studies need to be more thorough to efficiently enhance drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200, Brest, France; CHU de Brest, Service de Génétique Médicale et de Biologie de la Reproduction, F-29200 Brest, France.
- Department of Trauma Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
- Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200, Brest, France.
- Mines Saint-Etienne, Univ Lyon, Univ Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, F - 42023 Saint-Etienne, France.
- Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200, Brest, France; CHU de Brest, Service de Génétique Médicale et de Biologie de la Reproduction, F-29200 Brest, France. Electronic address: tristan.montier@univ-brest.fr.
Förderung
- Conseil Régional de Bretagne
- Agence Nationale de la Recherche
Zitieren
APA
Ghanem, R., Youf, R., Haute, T., Buin, X., Riool, M., Pourchez, J., & Montier, T. (2025). The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges. Journal of Controlled Release, 379, 421-439. https://doi.org/10.1016/j.jconrel.2025.01.017
Vancouver
Ghanem R, Youf R, Haute T, Buin X, Riool M, Pourchez J, et al. The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges. Journal of Controlled Release. 2025;379:421-439. doi:10.1016/j.jconrel.2025.01.017
BibTeX
@article{Ghanem2025,
author = {Ghanem, Rosy and Youf, Raphaëlle and Haute, Tanguy and Buin, Xavier and Riool, Martijn and Pourchez, Jérémie and Montier, Tristan},
title = {The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges},
journal = {Journal of Controlled Release},
year = {2025},
volume = {379},
pages = {421--439},
doi = {10.1016/j.jconrel.2025.01.017}
}
EUVIMED